Category: Curis

AACR Preview Part 6: CRIS INFI ISIS CLDX LGND ONXX PCYC

4/4/2013

In this post I will continue to highlight AACR abstracts relevant to the small-cap biotech companies that covered here at BiotechDueDiligence and/or may be of interest to readers.

Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)

0 Comments

CRIS - notes on ERIVEDGE from partner Roche earnings and annual report

3/7/2013

0 Comments

Curis Inc CRIS licensed their hedgehog inhibitor ERIVEDGE (vismodegib) to pharma giant Roche and the drug was approved for advanced basal cell carcinoma (BCC) in early 2012. Continue reading below for the latest updates on the marketing and continued development of the drug from Roche's 2012 year-end earnings release, conference call, and annual report.

0 Comments

CELG CELGZ THLD CRIS: Selected ASCO GI Abstracts

1/23/2013

0 Comments

The 2013 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2013) is set to take place January 24-26, 2013. So far the most buzz has been around the release of successful (but perhaps not as stupendous as some thought) phase 3 pancreatic cancer data for ABRAXANE from Celgene CELG.

The CELG data, Abraxane's likely FDA approval for pancreatic cancer (NDA anticipate 1h-2013), and the future sales of Abraxane are all key to the value of the CELGZ contingent value right (CVR) issued as part of the Abraxis buyout. Find all the CELGZ financial details here.

Continue reading below for the Celgene abstract as well as a couple of others from Threshold Pharma THLD (phase 2 pancreatic cancer data for TH-302 - not sure if anything new here, please let me know in the comments section if so) and Curis CRIS (another unsuccessful clinical trial of ERIVEDGE/vismodegib) in an indication other than basal cell carcinoma/BCC).

You can search all ASCO GI 2013 abstracts here.

0 Comments

Curis $CRIS - comments from Roche 2q2012 earnings re ERIVEDGE

8/27/2012

0 Comments

Curis $CRIS licensed their hedgehog inhibitor ERIVEDGE (vismodegib) to Roche. There was no mention of the drug on the 2q-2012 quarterly conference call. Sales have totaled about $10m since launch in early 2012 for advanced basal cell carcinoma (BCC), generating ~$0.5m in royalties to Curis. The earnings press release had the following update:

"Erivedge became the first and only FDA-approved treatment for advanced forms of basal cell carcinoma in February this year. It is also the first in a new class of anti-cancer treatments called hedgehog pathway inhibitors.Early market response is encouraging. Roche has submitted Erivedge for marketing approval in the EU, Australia, Mexico, Israel and Canada."

Approval in Europe is forecast to occur in 2h-2012 or early in 2013.

If interested, the drug was of course discussed in much greater detail on the CRIS quarterly call, including comments on sales growth, market dynamics, ongoing clinical trials, etc. Check it out on EarningsCast if interested.

0 Comments

Curis $CRIS ASCO 2012 Presentations

5/22/2012

6 Comments

Curis will present several abstracts at the upcoming ASCO 2012 meeting in June related to ERIVEDGE (vismodegib), the hedgehog inhibitor being developed and commercialized by Roche/Genentech $RHHBY and one on CUDC-101, another cancer candidate. Expand the full post to read the complete abstract texts.

6 Comments

<<Previous

AACR Preview Part 6: CRIS INFI ISIS CLDX LGND ONXX PCYC

CRIS - notes on ERIVEDGE from partner Roche earnings and annual report

CELG CELGZ THLD CRIS: Selected ASCO GI Abstracts

Curis $CRIS - comments from Roche 2q2012 earnings re ERIVEDGE

Curis $CRIS ASCO 2012 Presentations

Categories

Archives